AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Silence Therapeutics plc

Net Asset Value Jan 14, 2013

33536_rns_2013-01-14_da98ae9c-db72-49bc-ad3b-79db9b28a5e2.html

Net Asset Value

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5077V

Silence Therapeutics PLC

14 January 2013

London, 14 January 2013

Exercise of warrants - correction

This replaces the announcement released earlier today, 14 January 2013.  This morning's announcement incorrectly stated that ISM had 1.25m warrants remaining. The correct figure is 1.75m.

The Company announces that it has received notice from ISM Capital to exercise warrants over 1,750,000 ordinary shares of 0.1p each at an exercise price of 1 pence per Ordinary Share.  Accordingly, the Company will issue, in aggregate, 1,750,000 Ordinary Shares in settlement of this exercise. ISM has 1.75m warrants remaining.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares and application has been made for the new Ordinary Shares to be admitted to trading on AIM ("Admission").  It is expected that Admission will become effective and dealings in the new Ordinary Shares will commence at 8.00 a.m. on 15 January 2013.

Following the Warrant Exercise, the Company's issued share capital will consist of 0.1p       1,873,302,737 Ordinary Shares with voting rights.  This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

Silence Therapeutics

Tim Freeborn, finance director +44 20 7491 6520

[email protected]

Singer Capital Markets

Shaun Dobson/Jenny Wyllie

+44 20 32057500

[email protected]

[email protected]

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFIELFISLIV

Talk to a Data Expert

Have a question? We'll get back to you promptly.